Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748030 | 1.00 | KDM5A (0.36) | KDM5AADAM17CTSAALOX15ALDH1A1 | |
| SCHEMBL5758196 | 0.79 | — | — | |
| SCHEMBL5756848 | 0.79 | — | — | |
| SCHEMBL5757217 | 0.77 | IDO1 (0.36) | — | |
| SCHEMBL6746347 | 0.77 | CYP1A2 (0.30) | — | |
| SCHEMBL6746322 | 0.77 | CYP1A2 (0.30) | — | |
| SCHEMBL6746374 | 0.77 | IDO1 (0.36) | — | |
| SCHEMBL4595038 | 0.76 | CYP2D6 (0.49) | TSHR | |
| SCHEMBL1067441 | 0.74 | — | — | |
| SCHEMBL1067640 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | KDM5A 2534/4885ADAM17 4566/4885CTSA 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.